Kelly Dooley, MD, PhD

Faculty

Titles:

Associate Professor, Medicine and Pharmacology and Molecular Sciences

Email:

kdooley1@jhmi.edu

SciVal:

SciVal Link

Research focuses on clinical pharmacology of new anti-tuberculosis regimens with an emphasis on: (1) Phase I clinical trials of new or existing anti-TB drugs including dose escalation trials and studies of drug-drug interactions between anti-TB agents and antiretrovirals to treat HIV; (2) Use of PK/PD analysis and modelling in Phase II tuberculosis clinical treatment trials to determine concentration-effect relationships that will allow for optimization of dosing; and (3) Evaluation of TB and HIV drug concentrations in special populations, such as pregnant women and children; (4) Evaluation of treatment-shortening regimens for drug-sensitive TB and investigational regimens for treatment of multidrug-resistant TB; and (5) Translational work involving novel animal models of cavitary pulmonary TB disease to understand drug distribution in diseased lung.

Categories

Events

«

January 2022

»
S
M
T
W
T
F
S
·
·
·
·
·
·
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
·
·
·
·
·

Projects

A randomized trial of preventive therapy for...

We are evaluating the efficacy and cost-effectiveness of levofloxacin preventive therapy for adult contacts of MDR TB patients...

Read More

Comparative implementation and...

We are conducting a randomized comparative implementation trial across 56 sites in rural South Africa to evaluate three...

Read More

Understanding the impact of combined TB and...

We are developing models to understand the overlap of TB and HIV in three epidemiologically distinct settings (Canada, India,...

Read More

A Comprehensive Snapshot of Tuberculosis...

This study aims to find all cases of TB within an urban Ugandan community of 50,000 people and to characterize both the...

Read More